Perrigo Company plc

Valuation Analysis

About the Company

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessatio

Perrigo Company plc Stock at a Glance

Perrigo Company plc (PRGO) is currently trading at $10.99 with a market capitalization of $1.5B. The 52-week range spans from $9.23 to $28.44; the current price is 61.4% below the yearly high. Year-over-year revenue growth stands at -7.2%.

💰 Dividend

Perrigo Company plc pays an annual dividend of $1.16 per share, representing a yield of 10.56%. The payout ratio stands at 10950%. The elevated payout ratio reflects a mature dividend policy.

📊 Analyst Rating

4 analysts rate Perrigo Company plc (PRGO) on consensus: Buy. The average price target is $16.50, implying +50.14% from the current price. Analyst price targets range from $14.00 to $20.00.

Perrigo Company plc: The Investment Case in Detail

Perrigo Company plc (PRGO) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Ireland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 50.14% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue is contracting at -7.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 16.73% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The PEG ratio at 1.14 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 7.83x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 50.14% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (16.73%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Perrigo Company plc?

Compare top-rated brokers — low fees, trusted providers, fully regulated.